Alzheimer’s disease is a debilitating neurodegenerative disease and the most common form of dementia. Symptoms include irritability, confusion, mood swings, language difficulties and memory loss. Cognitive dysfunction becomes more pronounced as the disease progresses, leading to the loss of bodily functions and eventually death.
Alzheimer’s disease is characterized by the presence of amyloid plaques in the brain. Soluble beta-amyloid (Abeta) oligomers are thought to underlie the cognitive deficits associated with Alzheimer’s disease. Cognition Therapeutics therapies pharmacologically compete with Abeta oligomers for critical receptor targets preventing synapse loss and improving memory and their small molecule therapeutics act through molecular targets that have not been previously implicated in Alzheimer’s disease.
Cognition Therapeutics has received a US patent that describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Disease-relevant screening technologyclosely models the pathology of neurodegenerative diseases and novel, high-quality CNS-biased chemical libraries. These platforms can predict behavioral efficacy of candidate drugs in Alzheimer's models. U.S. National Stage Application: No. 13/263,162, entitled "Inhibitors of Cognitive Decline" was filed on October 6, 2011.
CogRx CEO Hank Safferstein said, "The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Kudos To "The Independent" Newspaper For Debunking Nibiru "Blood Moon" Hoax
- Dogs Understand Both Vocabulary And Intonation Of Human Speech
- Climate Change Has Less Impact On Drought Than Previously Expected
- Your Microbiome Did Not Cause Your Weight Problem
- Fewer Cardiovascular Drugs Being Studied In Clinical Trials
- State Of Academic Freedom 2016
- USDA Microbiologist Warns Bacteria In Vaping Products May Be A Health Concern
- "Apparently planet 9 exists. Not Nobiru but another dwarf planet. This planet could destroy a couple..."
- "Thank you. You know, I am of the firm belief that if a blog has a title that includes Science in..."
- "Firstly, I want to inform everyone apart from Kaylee that the following doesn't apply to the topic..."
- "Hello again Robert, Once again, thank you for your informative reply. It's wonderful to still find..."
- "Hi Margaret, thanks, glad you like my replay, and any views are welcome here :). It's only trolling..."
- <a href="/news/2016/08/30/some-sugars-help-babies-thrive-9934">Some Sugars Help Babies Thrive <i class="fa fa-angle-double-right"></i></a>
- <a href="/annual-reports">Annual Reports <i class="fa fa-angle-double-right"></i></a>
- <a href="/news/2016/08/29/icymi-acshs-most-popular-articles-summer-9931">ICYMI: ACSH's Most Popular Articles of the Summer <i class="fa fa-angle-double-right"></i></a>
- How Herpes Drugs Work
- The Infrared Sauna: Hollywood's Hot, Pricey 'Magic' Box
- E-Cigarette Flavors, Biotech Courts And More Media Links
- Progress in refining the genetic causes of schizophrenia
- Researchers discover machines can learn by simply observing
- Technique could assess historic changes to Antarctic sea ice and glaciers
- Factors associated with improvement in survival following heart attack
- System may help treat rare genetic disorder, reduce severe side effects